Abstract
Several animal models for the study of HIV/AIDS have been established and characterized and have been widely used to study the pathogenesis of HIV/AIDS as well as vaccine development. The purpose of this study was to review the literature and identify the animal models most frequently used for the evaluation of drugs, drug combinations, plant extracts and drug-plant combinations. Four of these animal models were evaluated namely the SIV model due to its similarities in pathogenesis of disease to humans, the FIV and the LP-BM5 model due to wide availability and the SCID murine model that combines components of both systems. The pathogenesis of disease in each model, application in the evaluation of drugs, drug combinations and plant extracts as well as the inherent advantages and disadvantages of each model are discussed. The LP-BM5 murine AIDS (MAIDS) model with its in vitro equivalent was identified as the animal model, although not identical to HIV/AIDS, most suitable for the rapid and cost effective initial screening of drugs, drug combinations, plant extracts and drug-plant combinations.
Keywords: antiretroviral, antiviral, SCID/HIV mouse LP-BM5/MAIDS, FIV, SIV, HIV/AIDS
Current HIV Research
Title: Animal Models Used for the Evaluation of Antiretroviral Therapies
Volume: 4 Issue: 4
Author(s): Andreia S.P. Dias, Megan J. Bester, Rozane F. Britz and Zeno Apostolides
Affiliation:
Keywords: antiretroviral, antiviral, SCID/HIV mouse LP-BM5/MAIDS, FIV, SIV, HIV/AIDS
Abstract: Several animal models for the study of HIV/AIDS have been established and characterized and have been widely used to study the pathogenesis of HIV/AIDS as well as vaccine development. The purpose of this study was to review the literature and identify the animal models most frequently used for the evaluation of drugs, drug combinations, plant extracts and drug-plant combinations. Four of these animal models were evaluated namely the SIV model due to its similarities in pathogenesis of disease to humans, the FIV and the LP-BM5 model due to wide availability and the SCID murine model that combines components of both systems. The pathogenesis of disease in each model, application in the evaluation of drugs, drug combinations and plant extracts as well as the inherent advantages and disadvantages of each model are discussed. The LP-BM5 murine AIDS (MAIDS) model with its in vitro equivalent was identified as the animal model, although not identical to HIV/AIDS, most suitable for the rapid and cost effective initial screening of drugs, drug combinations, plant extracts and drug-plant combinations.
Export Options
About this article
Cite this article as:
S.P. Dias Andreia, J. Bester Megan, F. Britz Rozane and Apostolides Zeno, Animal Models Used for the Evaluation of Antiretroviral Therapies, Current HIV Research 2006; 4 (4) . https://dx.doi.org/10.2174/157016206778560045
DOI https://dx.doi.org/10.2174/157016206778560045 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Endogenous Cardioprotective Agents: Role in Pre and Postconditioning
Current Drug Targets Mitochondrial Complex I Deficiency in Humans
Current Genomics Gender Disparities on Access to Care and Coronary Disease Management
Current Pharmaceutical Design Hemodynamic Assessment and In vivo Catabolism of Adenosine 5’-triphosphate in Doxorubicin or Isoproterenol-induced Cardiovascular Toxicity
Drug Metabolism Letters Pharmacogenomic Approaches for Tailored Anti-Leukemic Therapy in Children
Current Medicinal Chemistry Tissue Engineering Techniques in Cardiac Repair and Disease Modelling
Current Pharmaceutical Design Topoisomerase Enzymes as Therapeutic Targets for Cancer Chemotherapy
Medicinal Chemistry Valve Endothelial Cells – Not Just Any Old Endothelial Cells
Current Vascular Pharmacology Noncardiac Surgery: Evaluating and Minimizing Cardiac Risk
Current Cardiology Reviews Energizing Genetics and Epi-genetics: Role in the Regulation of Mitochondrial Function
Current Genomics Fluoride Interactions: From Molecules to Disease
Current Signal Transduction Therapy Cellular Iron Homeostasis and Therapeutic Implications of Iron Chelators in Cancer
Current Pharmaceutical Biotechnology Myocardial Infarction in Systemic Lupus Erythematosus – the Sex-Specific Risk Profile
Current Pharmaceutical Design Non-canonical Molecular Targets for Novel Analgesics: Intracellular Calcium and HCN Channels
Current Neuropharmacology Cardiac Fat as New Diagnostic Tool and Potential Therapeutic Target for Obesity Management and Treatment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Editorial [Hot Topic: Why Apoptosis in Pediatric Disorders?]
Current Pediatric Reviews Adrenomedullin: Roles for Structure and Function in Cardiac or Vascular Tissues
Current Hypertension Reviews Roles of p38-MAPK in Insulin Resistant Heart: Evidence from Bench to Future Bedside Application
Current Pharmaceutical Design Combinations Against Combinations: Associations of Anti-HIV 1 Reverse Transcriptase Drugs Challenged by Constellations of Drug Resistance Mutations
Current Drug Metabolism Regulatable Gene Expression Systems for Gene Therapy
Current Gene Therapy